S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Stocks are for suckers – try this instead (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Stocks are for suckers – try this instead (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Stocks are for suckers – try this instead (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Stocks are for suckers – try this instead (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Stocks are for suckers – try this instead (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Stocks are for suckers – try this instead (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Stocks are for suckers – try this instead (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Stocks are for suckers – try this instead (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
NASDAQ:MGNX

MacroGenics (MGNX) Stock Forecast, Price & News

$5.10
-0.05 (-0.97%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$5.00
$5.23
50-Day Range
$5.10
$7.54
52-Week Range
$2.13
$7.90
Volume
601,400 shs
Average Volume
578,651 shs
Market Capitalization
$315.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.40

MacroGenics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.55 Rating Score
Upside/​Downside
123.5% Upside
$11.40 Price Target
Short Interest
Bearish
8.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.61
Upright™ Environmental Score
News Sentiment
0.63mentions of MacroGenics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$32,393 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.62) to ($1.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

663rd out of 1,010 stocks

Pharmaceutical Preparations Industry

337th out of 494 stocks


MGNX stock logo

About MacroGenics (NASDAQ:MGNX) Stock

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Stock News Headlines

MacroGenics (NASDAQ:MGNX) Upgraded at StockNews.com
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
MacroGenics (NASDAQ:MGNX) Downgraded by StockNews.com
JMP Securities Sticks to Their Buy Rating for MacroGenics (MGNX)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Earnings Outlook For Macrogenics
MacroGenics: Q1 Earnings Snapshot
MacroGenics (MGNX) Gets a Buy from BTIG
MacroGenics (MGNX) Q1 2023 Earnings Call Transcript
MacroGenics (MGNX) Set to Announce Earnings on Tuesday
H.C. Wainwright Remains a Buy on MacroGenics (MGNX)
MacroGenics' (MGNX) "Buy" Rating Reaffirmed at HC Wainwright
See More Headlines
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Company Calendar

Last Earnings
3/15/2023
Today
5/29/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGNX
Employees
427
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$11.40
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+123.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55
Research Coverage
11 Analysts

Profitability

Net Income
$-119,760,000.00
Pretax Margin
-55.24%

Debt

Sales & Book Value

Annual Sales
$151.94 million
Book Value
$1.77 per share

Miscellaneous

Free Float
55,655,000
Market Cap
$315.38 million
Optionable
Optionable
Beta
2.00

Social Links


Key Executives

  • Scott E. Koenig
    President, Chief Executive Officer & Director
  • Eric Risser
    Chief Operating Officer
  • James KarrelsJames Karrels
    Chief Financial Officer, Secretary & Senior VP
  • Ezio Bonvini
    Chief Scientific Officer & Senior VP-Research
  • Thomas M. SpitznagelThomas M. Spitznagel
    Senior Vice President-Technical Operations













MGNX Stock - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last twelve months. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares.
View MGNX analyst ratings
or view top-rated stocks.

What is MacroGenics' stock price forecast for 2023?

11 equities research analysts have issued 12 month target prices for MacroGenics' stock. Their MGNX share price forecasts range from $5.00 to $17.00. On average, they predict the company's share price to reach $11.40 in the next year. This suggests a possible upside of 123.5% from the stock's current price.
View analysts price targets for MGNX
or view top-rated stocks among Wall Street analysts.

How have MGNX shares performed in 2023?

MacroGenics' stock was trading at $6.71 on January 1st, 2023. Since then, MGNX stock has decreased by 24.0% and is now trading at $5.10.
View the best growth stocks for 2023 here
.

When is MacroGenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our MGNX earnings forecast
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) issued its quarterly earnings results on Wednesday, March, 15th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.51. The biopharmaceutical company earned $73.10 million during the quarter, compared to analysts' expectations of $75.40 million. MacroGenics had a negative trailing twelve-month return on equity of 70.69% and a negative net margin of 55.24%.

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?
What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.70%), Armistice Capital LLC (9.64%), Wasatch Advisors LP (2.14%), State Street Corp (2.11%), Acadian Asset Management LLC (1.99%) and Geode Capital Management LLC (1.88%). Insiders that own company stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends
.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $5.10.

How much money does MacroGenics make?

MacroGenics (NASDAQ:MGNX) has a market capitalization of $315.38 million and generates $151.94 million in revenue each year. The biopharmaceutical company earns $-119,760,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

How many employees does MacroGenics have?

The company employs 427 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for the company is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321.

This page (NASDAQ:MGNX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -